Company intelligence / Profile preview

28 Capital

Boston/Waltham, Massachusetts, United Statestigergene.com ↗

Ownership: Private
Development stage: Other

Overview

As "Tiger Gene," now "28 Capital," the firm has seeded and built multiple transformative biotech startups focused on breakthrough therapies and synthetic biology platforms. It partners closely with academic founders to translate foundational science into scalable businesses.

Modalities: Small moleculeMonoclonal antibodySynthetic biology platformsDiagnostics
Industry: Investors

Partnerships

Leading scientistsAcademic institutions (e.g., Harvard University)Principal investigators for company creationTiger Management L.L.C.

Beyond the preview

Go deeper on 28 Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 28 Capital.

Explore the full profile